Compound 222, in contrast, was the only metabolite found to be a potent dual agonist of both PPARα and PPARγ (50 μM= 2.13-fold induction; 25 μM= 1.85-fold induction; 12.5 μM= 1.42-fold induction), and its activity represents a great potential for the treatment of metabolic disorders. Here, PPARG is linked to metabolic disease.